Cargando…

Downregulation of LOX promotes castration-resistant prostate cancer progression via IGFBP3

The role of lysyl oxidase (LOX) in prostate cancer remains controversial. Studies have shown that LOX may inhibit the progression of prostate cancer (PCa), whereas other studies demonstrate that LOX may act as a tumor activator in PCa. Here, we report that low LOX expression contributes to CRPC prog...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Xuanrong, Shao, Yi, Wei, Wanqing, Shen, Haishan, Li, Yang, Chen, Yutong, Ma, Qianwang, Li, Hanlin, Yang, Zhao, Niu, Yuanjie, Shang, Zhiqun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8734407/ https://www.ncbi.nlm.nih.gov/pubmed/35003355 http://dx.doi.org/10.7150/jca.61131

Ejemplares similares

A narrative review of proteolytic targeting chimeras (PROTACs): future perspective for prostate cancer therapy
por: Chen, Xuanrong, et al.
Publicado: (2021)

Super-enhancer in prostate cancer: transcriptional disorders and therapeutic targets
por: Chen, Xuanrong, et al.
Publicado: (2020)

Post-transcriptional modification of m(6)A methylase METTL3 regulates ERK-induced androgen-deprived treatment resistance prostate cancer
por: Li, Yang, et al.
Publicado: (2023)

Increased expression of CELSR3 indicates a poor prognostic factor for Prostate Cancer
por: Chen, Xuanrong, et al.
Publicado: (2021)

Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer
por: Chen, Xuanrong, et al.
Publicado: (2022)

Correction: Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer
por: Chen, Xuanrong, et al.
Publicado: (2023)

The cell cycle gene centromere protein K (CENPK) contributes to the malignant progression and prognosis of prostate cancer
por: Chen, Xuanrong, et al.
Publicado: (2022)

HOXB3 drives WNT-activation associated progression in castration-resistant prostate cancer
por: Zhu, Shimiao, et al.
Publicado: (2023)

Increased KIF4A expression is a potential prognostic factor in prostate cancer
por: Gao, Hongwei, et al.
Publicado: (2018)

YAP1 plays a key role of the conversion of normal fibroblasts into cancer-associated fibroblasts that contribute to prostate cancer progression
por: Shen, Tianyu, et al.
Publicado: (2020)

Assessing the Potential Prognostic and Immunological Role of TK1 in Prostate Cancer
por: Xie, Hui, et al.
Publicado: (2022)

YAP is required for prostate development, regeneration, and prostate stem cell function
por: Xie, Hui, et al.
Publicado: (2023)

High Expression of KIF22/Kinesin-Like DNA Binding Protein (Kid) as a Poor Prognostic Factor in Prostate Cancer Patients
por: Zhang, Zheng, et al.
Publicado: (2018)

Neutrophil–lymphocyte ratio is a predictor of prognosis in patients with castration-resistant prostate cancer: a meta-analysis
por: Wang, Zhun, et al.
Publicado: (2018)

CDCA5 promotes the progression of prostate cancer by affecting the ERK signalling pathway
por: Ji, Junpeng, et al.
Publicado: (2021)

[Corrigendum] CDCA5 promotes the progression of prostate cancer by affecting the ERK signalling pathway
por: Ji, Junpeng, et al.
Publicado: (2023)

AB007. Neurotensin derived from cancer stroma contributes to castration resistance via promoting neuroendocrine transdifferentiation
por: Zhu, Shimiao, et al.
Publicado: (2016)

YAP1 regulates prostate cancer stem cell-like characteristics to promote castration resistant growth
por: Jiang, Ning, et al.
Publicado: (2017)

Neurotensin and its receptors mediate neuroendocrine transdifferentiation in prostate cancer
por: Zhu, Shimiao, et al.
Publicado: (2019)

Correction: Neurotensin and its receptors mediate neuroendocrine transdifferentiation in prostate cancer
por: Zhu, Shimiao, et al.
Publicado: (2019)

CYTOR drives prostate cancer progression via facilitating AR‐V7 generation and its oncogenic signalling
por: Yu, Jianpeng, et al.
Publicado: (2023)

LncRNA PCAT1 activates AKT and NF-κB signaling in castration-resistant prostate cancer by regulating the PHLPP/FKBP51/IKKα complex
por: Shang, Zhiqun, et al.
Publicado: (2019)

Identification of Neoantigens and Construction of Immune Subtypes in Prostate Adenocarcinoma
por: Gao, Yukui, et al.
Publicado: (2022)

Aberrant KIF20A Expression Is Associated with Adverse Clinical Outcome and Promotes Tumor Progression in Prostate Cancer
por: Zhang, Zheng, et al.
Publicado: (2019)

Alterations of plasma exosomal proteins and motabolies are associated with the progression of castration-resistant prostate cancer
por: Liu, Pengyu, et al.
Publicado: (2023)

Androgen receptor-mediated downregulation of microRNA-221 and -222 in castration-resistant prostate cancer
por: Gui, Bin, et al.
Publicado: (2017)

LOX inhibition downregulates MMP-2 and MMP-9 in gastric cancer tissues and cells
por: Zhao, Lei, et al.
Publicado: (2019)

Risk factors for progression to castration-resistant prostate cancer in metastatic prostate cancer patients
por: Lin, Ting-Ting, et al.
Publicado: (2019)

Epigenetic Downregulation and Growth Inhibition of IGFBP7 in Gastric Cancer
por: Kim, Jin, et al.
Publicado: (2018)

Fusion Protein Vaccine Based on Ag85B and STEAP1 Induces a Protective Immune Response against Prostate Cancer
por: Guo, Linpei, et al.
Publicado: (2021)

HSP60, a protein downregulated by IGFBP7 in colorectal carcinoma
por: Ruan, Wenjing, et al.
Publicado: (2010)

P300/SP1 complex mediating elevated METTL1 regulates CDK14 mRNA stability via internal m7G modification in CRPC
por: Zhang, Mingpeng, et al.
Publicado: (2023)

Castration-Induced Downregulation of SPARC in Stromal Cells Drives Neuroendocrine Differentiation of Prostate Cancer
por: Enriquez, Claudia, et al.
Publicado: (2021)

Genetic Polymorphisms in IGF-I and IGFBP-3 Are Associated with Prostate Cancer in the Chinese Population
por: Qian, Jian, et al.
Publicado: (2014)

Downregulation of CD147 induces malignant melanoma cell apoptosis via the regulation of IGFBP2 expression
por: Zhao, Shuang, et al.
Publicado: (2018)

Integrated network model provides new insights into castration-resistant prostate cancer
por: Hu, Yanling, et al.
Publicado: (2015)

The MAO inhibitors phenelzine and clorgyline revert enzalutamide resistance in castration resistant prostate cancer
por: Wang, Keliang, et al.
Publicado: (2020)

A switch from CD44(+) cell to EMT cell drives the metastasis of prostate cancer
por: Shang, Zhiqun, et al.
Publicado: (2014)

Increased CK5/CK8-Positive Intermediate Cells with Stromal Smooth Muscle Cell Atrophy in the Mice Lacking Prostate Epithelial Androgen Receptor
por: Niu, Yuanjie, et al.
Publicado: (2011)

What is the next generation therapeutic strategy for castration-resistant prostate cancer
por: Wen, Si-Meng, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_2fg9js6g65ffhlgpr4s7g7iqe2